Penumbra Inc.
Penumbra Reports Strong Q3 2024 Financial Results with Revenue Growth
Summary
Penumbra, Inc. reported a significant increase in revenue for the third quarter of 2024, with total revenue at $301.0 million, up 11.1% year-over-year. The company's net income was $29.5 million, and non-GAAP income from operations was $40.3 million. Adjusted EBITDA stood at $56.7 million. The financial results were driven by strong growth in U.S. thrombectomy revenue, which increased by 21.2% year-over-year. The company also reiterated its guidance for full-year 2024 revenue in the range of $1,180.0 million to $1,200.0 million.
Profitelligence Alerts
Get alerts for PEN
Be first to know when Penumbra Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Penumbra Inc.
Penumbra Inc. is a prominent player in the healthcare sector, focusing primarily on the development and commercialization of innovative medical devices. Known for its customer-centric approach, the company operates within the specialized field of interventional therapies, particularly in neuro and vascular medical devices. Penumbra’s products are crucial for addressing critical conditions such as stroke and peripheral artery diseases. By pioneering minimally invasive solutions, the company significantly contributes to enhancing patient outcomes and reshaping intervention methods in the medical field. Founded in 2004 and headquartered in Alameda, California, Penumbra plays a vital role in the medical device industry with its commitment to advancing healthcare technologies. Its solutions are not only pivotal in specialized medical procedures but also support the healthcare ecosystem's broader objective of improving care and saving lives, making it a key entity amongst healthcare providers and hospitals worldwide.
Official SEC Documents
Advertisement